Chris Brown

M.S. Data Science

Antiphospholipid Syndrome: Unraveling Adverse Outcomes in Pregnancy

Antiphospholipid syndrome (APS) refers to the clinical association between antiphospholipid antibodies and a hypercoagulable state, which increases the risk of blood clot formation within blood vessels. APS is more prevalent in women than in men. Research shows that women with APS face an elevated risk of adverse pregnancy outcomes, particularly during the fetal period (ten or more weeks of gestation). These outcomes include preeclampsia, characterized by high blood pressure and proteinuria (excess protein in urine), recurrent early pregnancy loss, fetal demise, and intrauterine growth restriction. APS-related pregnancy losses tend to occur later in pregnancy compared to sporadic or recurrent miscarriages, which typically happen earlier in the pre-embryonic or embryonic period. Factors such as placental insufficiency, hypertensive disorders of pregnancy, thrombophilia, and underlying autoimmune conditions play a role. This research aims to study the complex interplay of these factors to improve outcomes for affected women. Notably, APS is more prevalent among underserved communities.